TGFB1 and Ureteral obstruction: BAY PP1, a novel PPAR-α agonist, significantly reduced tubulointerstitial fibrosis, TGF-β expression, and proliferation of interstitial fibroblasts in unilateral ureteral obstruction and 5/6 nephrectomy models [11].